To assess the efficacy of FGF-21, Metrnl, and sortilin as biomarkers for differentiating individuals with metabolic syndrome, insulin resistance, carbohydrate disorders, and dyslipidemia, receiver operating characteristic (ROC) curve analysis was performed. This evidence concerns the gene FGF21 and metabolic syndrome.